Syed Imran Ali Shah

Learn More
Androgen deprivation therapy (ADT) resulting in testosterone suppression is central to the management of prostate cancer (PC). As PC incidence increases, ADT is more frequently prescribed, and for longer periods of time as survival improves. Initial approaches to ADT included orchiectomy or oral estrogen (diethylstilbestrol [DES]). DES reduces PC-specific(More)
Sir, Bourke et al (2013) raise important and topical issues concerning the expanding literature and consequent increasingly informed debate surrounding the risks, benefits and costeffectiveness of androgen deprivation therapy (ADT) in advanced prostate cancer (Bourke et al, 2013). It was disappointing, therefore, that their review did not incorporate a more(More)
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information(More)
Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in “castration syndrome”, a constellation of adverse events such as muscle weakness, impairment of(More)
  • 1